$NOVN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NOVEN PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NOVEN PHARMACEUTICALS INC. Get notifications about new insider transactions in NOVEN PHARMACEUTICALS INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 30 2006 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Buy | M | 13.11 | 8,332 | 109,233 | 26,846 | 18.5 K to 26.8 K (+45.00 %) |
Aug 30 2006 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Buy | M | 15.13 | 16,002 | 242,110 | 18,514 | 2.5 K to 18.5 K (+637.02 %) |
Aug 24 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 12.94 | 30,900 | 399,769 | 0 | |
Aug 24 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 12.94 | 22,848 | 295,596 | 30,900 | |
Aug 24 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Sell | S | 22.75 | 30,900 | 702,975 | 175,937 | 206.8 K to 175.9 K (-14.94 %) |
Aug 24 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Buy | M | 12.94 | 30,900 | 399,769 | 206,837 | 175.9 K to 206.8 K (+17.56 %) |
Aug 24 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Sell | S | 22.76 | 100 | 2,276 | 175,937 | 176 K to 175.9 K (-0.06 %) |
Aug 24 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Sell | S | 22.75 | 22,748 | 517,517 | 176,037 | 198.8 K to 176 K (-11.44 %) |
Aug 24 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Buy | M | 12.94 | 22,848 | 295,596 | 198,785 | 175.9 K to 198.8 K (+12.99 %) |
Aug 22 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 12.94 | 4,164 | 53,872 | 53,748 | |
Aug 22 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Sell | S | 22.77 | 300 | 6,831 | 175,937 | 176.2 K to 175.9 K (-0.17 %) |
Aug 22 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Sell | S | 22.75 | 3,864 | 87,906 | 176,237 | 180.1 K to 176.2 K (-2.15 %) |
Aug 22 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Buy | M | 12.94 | 4,164 | 53,872 | 180,101 | 175.9 K to 180.1 K (+2.37 %) |
Aug 15 2006 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Option Exercise | M | 10.00 | 5,405 | 54,050 | 0 | |
Aug 15 2006 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Sell | S | 20.27 | 15,146 | 306,940 | 6,700 | 21.8 K to 6.7 K (-69.33 %) |
Aug 15 2006 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Sell | S | 20.27 | 5,405 | 109,534 | 21,846 | 27.3 K to 21.8 K (-19.83 %) |
Aug 15 2006 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Buy | M | 10.00 | 5,405 | 54,050 | 27,251 | 21.8 K to 27.3 K (+24.74 %) |
Aug 11 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Option Exercise | M | 8.81 | 5,100 | 44,931 | 0 | |
Aug 11 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Payment of Exercise | F | 20.79 | 2,161 | 44,927 | 6,339 | 8.5 K to 6.3 K (-25.42 %) |
Aug 11 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Buy | M | 8.81 | 5,100 | 44,931 | 8,500 | 3.4 K to 8.5 K (+150.00 %) |
Aug 09 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Option Exercise | M | 10.45 | 6,666 | 69,660 | 10,001 | |
Aug 09 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Option Exercise | M | 11.12 | 8,638 | 96,055 | 30,000 | |
Aug 09 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Sell | S | 21.00 | 6,666 | 139,986 | 0 | 6.7 K to 0 (-100.00 %) |
Aug 09 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Buy | M | 10.45 | 6,666 | 69,660 | 6,666 | 0 to 6.7 K |
Aug 09 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Sell | S | 21.00 | 8,638 | 181,398 | 0 | 8.6 K to 0 (-100.00 %) |
Aug 09 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Buy | M | 11.12 | 8,638 | 96,055 | 8,638 | 0 to 8.6 K |
Aug 03 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Option Exercise | M | 11.12 | 11,362 | 126,345 | 38,638 | |
Aug 03 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Sell | S | 21.01 | 400 | 8,404 | 0 | 400 to 0 (-100.00 %) |
Aug 03 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Sell | S | 21.00 | 10,962 | 230,202 | 400 | 11.4 K to 400 (-96.48 %) |
Aug 03 2006 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Buy | M | 11.12 | 11,362 | 126,345 | 11,362 | 0 to 11.4 K |
Jul 26 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Option Exercise | M | 10.00 | 18,000 | 180,000 | 0 | |
Jul 26 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Sell | S | 20.00 | 18,000 | 360,000 | 3,400 | 21.4 K to 3.4 K (-84.11 %) |
Jul 26 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Buy | M | 10.00 | 18,000 | 180,000 | 21,400 | 3.4 K to 21.4 K (+529.41 %) |
Jun 19 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 12.94 | 4,588 | 59,357 | 57,912 | |
Jun 19 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Buy | M | 12.94 | 4,588 | 59,357 | 175,937 | 171.3 K to 175.9 K (+2.68 %) |
May 25 2006 | NOVN | NOVEN PHARMACEUTIC ... | YETTER WAYNE P | Director | Grant | A | 0.00 | 5,724 | 0 | 6,818 | 1.1 K to 6.8 K (+523.22 %) |
May 25 2006 | NOVN | NOVEN PHARMACEUTIC ... | SAVAGE ROBERT G | Director | Grant | A | 0.00 | 5,724 | 0 | 6,124 | 400 to 6.1 K (+1,431.00 %) |
May 25 2006 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Grant | A | 0.00 | 5,724 | 0 | 5,882 | 158 to 5.9 K (+3,622.78 %) |
May 25 2006 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Grant | A | 0.00 | 5,724 | 0 | 6,124 | 400 to 6.1 K (+1,431.00 %) |
May 25 2006 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Grant | A | 0.00 | 5,724 | 0 | 6,052 | 328 to 6.1 K (+1,745.12 %) |
May 25 2006 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Grant | A | 0.00 | 5,724 | 0 | 12,818 | 7.1 K to 12.8 K (+80.69 %) |
Mar 20 2006 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Option Exercise | M | 10.00 | 3,250 | 32,500 | 0 | |
Mar 20 2006 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 17.01 | 3,250 | 55,283 | 2,512 | 5.8 K to 2.5 K (-56.40 %) |
Mar 20 2006 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Buy | M | 10.00 | 3,250 | 32,500 | 5,762 | 2.5 K to 5.8 K (+129.38 %) |
Mar 17 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Option Exercise | M | 8.81 | 9,500 | 83,695 | 5,100 | |
Mar 17 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Sell | S | 17.36 | 4,000 | 69,450 | 3,400 | 7.4 K to 3.4 K (-54.05 %) |
Mar 17 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Sell | S | 17.31 | 2,000 | 34,620 | 7,400 | 9.4 K to 7.4 K (-21.28 %) |
Mar 17 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Sell | S | 17.28 | 3,500 | 60,480 | 9,400 | 12.9 K to 9.4 K (-27.13 %) |
Mar 17 2006 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Buy | M | 8.81 | 9,500 | 83,695 | 12,900 | 3.4 K to 12.9 K (+279.41 %) |
Jan 12 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 5.63 | 40,000 | 225,000 | 0 | |
Jan 12 2006 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Buy | M | 5.63 | 40,000 | 225,000 | 171,349 | 131.3 K to 171.3 K (+30.45 %) |
Nov 17 2005 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | A | 13.68 | 107,407 | 1,469,328 | 107,407 | |
Nov 17 2005 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Option Exercise | A | 13.68 | 30,864 | 422,220 | 30,864 | |
Nov 17 2005 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Option Exercise | A | 13.68 | 30,864 | 422,220 | 30,864 | |
Nov 17 2005 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Sr. VP - Strategic ... | Option Exercise | A | 13.68 | 30,864 | 422,220 | 30,864 | |
Nov 17 2005 | NOVN | NOVEN PHARMACEUTIC ... | BARRETT DIANE | VP & Chief Financia ... | Option Exercise | A | 13.68 | 30,864 | 422,220 | 30,864 | |
Nov 17 2005 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Option Exercise | A | 13.68 | 30,864 | 422,220 | 30,864 | |
Aug 24 2005 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Option Exercise | M | 5.56 | 1,250 | 6,950 | 0 | |
Aug 24 2005 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Option Exercise | M | 4.19 | 1,500 | 6,285 | 0 | |
Aug 24 2005 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Sell | S | 15.99 | 1,250 | 19,988 | 21,846 | 23.1 K to 21.8 K (-5.41 %) |
Aug 24 2005 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Buy | M | 5.56 | 1,250 | 6,950 | 23,096 | 21.8 K to 23.1 K (+5.72 %) |
Aug 24 2005 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Sell | S | 15.99 | 1,500 | 23,985 | 21,846 | 23.3 K to 21.8 K (-6.43 %) |
Aug 24 2005 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Buy | M | 4.19 | 1,500 | 6,285 | 23,346 | 21.8 K to 23.3 K (+6.87 %) |
May 25 2005 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Option Exercise | A | 17.41 | 7,500 | 130,575 | 7,500 | |
May 25 2005 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Option Exercise | A | 17.41 | 7,500 | 130,575 | 7,500 | |
May 25 2005 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Option Exercise | A | 17.41 | 7,500 | 130,575 | 7,500 | |
May 25 2005 | NOVN | NOVEN PHARMACEUTIC ... | YETTER WAYNE P | Director | Option Exercise | A | 17.41 | 7,500 | 130,575 | 7,500 | |
May 25 2005 | NOVN | NOVEN PHARMACEUTIC ... | SAVAGE ROBERT G | Director | Option Exercise | A | 17.41 | 7,500 | 130,575 | 7,500 | |
May 25 2005 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Option Exercise | A | 17.41 | 7,500 | 130,575 | 7,500 | |
Jan 25 2005 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Option Exercise | M | 8.67 | 652 | 5,653 | 0 | |
Jan 25 2005 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP and Chief Techni ... | Buy | M | 8.67 | 652 | 5,653 | 21,846 | 21.2 K to 21.8 K (+3.08 %) |
Nov 18 2004 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Option Exercise | A | 22.53 | 15,000 | 337,950 | 15,000 | |
Nov 18 2004 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Grant | A | 0.00 | 158 | 0 | 158 | 0 to 158 |
Nov 15 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Option Exercise | M | 6.03 | 5,000 | 30,156 | 0 | |
Nov 15 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Option Exercise | M | 6.00 | 5,000 | 30,000 | 0 | |
Nov 15 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Option Exercise | M | 8.13 | 5,000 | 40,650 | 0 | |
Nov 15 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Sell | S | 22.49 | 5,000 | 112,450 | 7,094 | 12.1 K to 7.1 K (-41.34 %) |
Nov 15 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Buy | M | 6.03 | 5,000 | 30,156 | 12,094 | 7.1 K to 12.1 K (+70.48 %) |
Nov 15 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Sell | S | 22.49 | 5,000 | 112,450 | 7,094 | 12.1 K to 7.1 K (-41.34 %) |
Nov 15 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Buy | M | 6.00 | 5,000 | 30,000 | 12,094 | 7.1 K to 12.1 K (+70.48 %) |
Nov 15 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Sell | S | 22.49 | 5,000 | 112,450 | 7,094 | 12.1 K to 7.1 K (-41.34 %) |
Nov 15 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Buy | M | 8.13 | 5,000 | 40,650 | 12,094 | 7.1 K to 12.1 K (+70.48 %) |
Nov 12 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | A | 22.60 | 100,000 | 2,260,000 | 100,000 | |
Nov 12 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP - Marketing & Sa ... | Option Exercise | A | 22.60 | 50,000 | 1,130,000 | 50,000 | |
Nov 12 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Option Exercise | A | 22.60 | 50,000 | 1,130,000 | 50,000 | |
Nov 12 2004 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | VP & General Counse ... | Option Exercise | A | 22.60 | 50,000 | 1,130,000 | 50,000 | |
Nov 12 2004 | NOVN | NOVEN PHARMACEUTIC ... | ABRAO EDUARDO G | VP & Chief Medical ... | Option Exercise | A | 22.60 | 50,000 | 1,130,000 | 50,000 | |
Nov 12 2004 | NOVN | NOVEN PHARMACEUTIC ... | BARRETT DIANE | VP & Chief Financia ... | Option Exercise | A | 22.60 | 50,000 | 1,130,000 | 50,000 | |
Sep 10 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Option Exercise | M | 10.00 | 4,595 | 45,950 | 5,405 | |
Sep 10 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Option Exercise | M | 5.56 | 11,250 | 62,550 | 1,250 | |
Sep 10 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Option Exercise | M | 4.19 | 3,500 | 14,665 | 1,500 | |
Sep 10 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Option Exercise | M | 8.67 | 1,849 | 16,031 | 652 | |
Sep 10 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Payment of Exercise | F | 20.77 | 6,700 | 139,159 | 21,194 | 27.9 K to 21.2 K (-24.02 %) |
Sep 10 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Buy | M | 10.00 | 4,595 | 45,950 | 27,894 | 23.3 K to 27.9 K (+19.72 %) |
Sep 10 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Buy | M | 5.56 | 11,250 | 62,550 | 23,299 | 12 K to 23.3 K (+93.37 %) |
Sep 10 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Buy | M | 4.19 | 3,500 | 14,665 | 12,049 | 8.5 K to 12 K (+40.94 %) |
Sep 10 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Buy | M | 8.67 | 1,849 | 16,031 | 8,549 | 6.7 K to 8.5 K (+27.60 %) |
Jul 30 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 5.63 | 10,000 | 56,250 | 40,000 | |
Jul 30 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Buy | M | 5.63 | 10,000 | 56,250 | 131,349 | 121.3 K to 131.3 K (+8.24 %) |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | YETTER WAYNE P | Director | Option Exercise | A | 18.73 | 7,500 | 140,475 | 7,500 | |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | YETTER WAYNE P | Director | Grant | A | 0.00 | 400 | 0 | 1,094 | 694 to 1.1 K (+57.64 %) |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Option Exercise | A | 18.73 | 7,500 | 140,475 | 7,500 | |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Grant | A | 0.00 | 400 | 0 | 7,094 | 6.7 K to 7.1 K (+5.98 %) |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | SAVAGE ROBERT G | Director | Option Exercise | A | 18.73 | 7,500 | 140,475 | 7,500 | |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | SAVAGE ROBERT G | Director | Grant | A | 0.00 | 400 | 0 | 400 | 0 to 400 |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Option Exercise | A | 18.73 | 7,500 | 140,475 | 7,500 | |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Grant | A | 0.00 | 400 | 0 | 400 | 0 to 400 |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Option Exercise | A | 18.73 | 7,500 | 140,475 | 7,500 | |
May 19 2004 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Option Exercise | A | 18.73 | 7,500 | 140,475 | 7,500 | |
Mar 09 2004 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | VP & General Counse ... | Option Exercise | M | 8.81 | 3,400 | 29,954 | 14,600 | |
Mar 09 2004 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | VP & General Counse ... | Option Exercise | M | 4.38 | 14,000 | 61,320 | 0 | |
Mar 09 2004 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | VP & General Counse ... | Payment of Exercise | F | 23.95 | 1,250 | 29,938 | 3,400 | 4.7 K to 3.4 K (-26.88 %) |
Mar 09 2004 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | VP & General Counse ... | Buy | M | 8.81 | 3,400 | 29,954 | 4,650 | 1.3 K to 4.7 K (+272.00 %) |
Mar 09 2004 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | VP & General Counse ... | Sell | S | 23.50 | 5,000 | 117,500 | 1,250 | 6.3 K to 1.3 K (-80.00 %) |
Mar 09 2004 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | VP & General Counse ... | Sell | S | 23.55 | 5,000 | 117,750 | 6,250 | 11.3 K to 6.3 K (-44.44 %) |
Mar 09 2004 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | VP & General Counse ... | Sell | S | 23.58 | 4,000 | 94,320 | 11,250 | 15.3 K to 11.3 K (-26.23 %) |
Mar 09 2004 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | VP & General Counse ... | Buy | M | 4.38 | 14,000 | 61,320 | 15,250 | 1.3 K to 15.3 K (+1,120.00 %) |
Mar 08 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Sell | S | 23.93 | 7,067 | 169,113 | 6,700 | 13.8 K to 6.7 K (-51.33 %) |
Mar 08 2004 | NOVN | NOVEN PHARMACEUTIC ... | MANTELLE JUAN A | VP & Chief Technica ... | Sell | S | 23.77 | 5,000 | 118,850 | 13,767 | 18.8 K to 13.8 K (-26.64 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Option Exercise | M | 15.13 | 15,998 | 242,050 | 24,002 | |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Option Exercise | M | 10.00 | 3,033 | 30,330 | 3,250 | |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Option Exercise | M | 10.00 | 6,717 | 67,170 | 3,033 | |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.00 | 16,880 | 405,120 | 2,512 | 19.4 K to 2.5 K (-87.05 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.01 | 100 | 2,401 | 19,392 | 19.5 K to 19.4 K (-0.51 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.03 | 1,100 | 26,433 | 19,492 | 20.6 K to 19.5 K (-5.34 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.04 | 951 | 22,862 | 20,592 | 21.5 K to 20.6 K (-4.41 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Buy | M | 15.13 | 15,998 | 242,050 | 21,543 | 5.5 K to 21.5 K (+288.51 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Buy | M | 10.00 | 3,033 | 30,330 | 5,545 | 2.5 K to 5.5 K (+120.74 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.00 | 6,717 | 161,208 | 2,512 | 9.2 K to 2.5 K (-72.78 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Buy | M | 10.00 | 6,717 | 67,170 | 9,229 | 2.5 K to 9.2 K (+267.40 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Option Exercise | M | 15.13 | 15,998 | 242,050 | 24,002 | |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Option Exercise | M | 10.00 | 3,033 | 30,330 | 3,250 | |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Option Exercise | M | 10.00 | 6,717 | 67,170 | 3,033 | |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.00 | 16,880 | 405,120 | 2,512 | 19.4 K to 2.5 K (-87.05 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.01 | 100 | 2,401 | 19,392 | 19.5 K to 19.4 K (-0.51 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.03 | 1,100 | 26,433 | 19,492 | 20.6 K to 19.5 K (-5.34 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.04 | 951 | 22,862 | 20,592 | 21.5 K to 20.6 K (-4.41 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Buy | M | 15.13 | 15,998 | 242,050 | 21,543 | 5.5 K to 21.5 K (+288.51 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Buy | M | 10.00 | 3,033 | 30,330 | 5,545 | 2.5 K to 5.5 K (+120.74 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Sell | S | 24.00 | 6,717 | 161,208 | 2,512 | 9.2 K to 2.5 K (-72.78 %) |
Mar 05 2004 | NOVN | NOVEN PHARMACEUTIC ... | JONES W NEIL | VP, Marketing & Sal ... | Buy | M | 10.00 | 6,717 | 67,170 | 9,229 | 2.5 K to 9.2 K (+267.40 %) |
Mar 03 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 6.18 | 630 | 3,893 | 0 | |
Mar 03 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 6.18 | 49,782 | 307,653 | 630 | |
Mar 03 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 6.18 | 19,765 | 122,148 | 50,412 | |
Mar 03 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Option Exercise | M | 6.18 | 45,000 | 278,100 | 70,177 | |
Mar 03 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Sell | S | 23.26 | 630 | 14,654 | 121,349 | 122 K to 121.3 K (-0.52 %) |
Mar 03 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Buy | M | 6.18 | 630 | 3,893 | 121,979 | 121.3 K to 122 K (+0.52 %) |
Mar 03 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Sell | S | 22.07 | 5,000 | 110,350 | 121,349 | 126.3 K to 121.3 K (-3.96 %) |
Mar 03 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Sell | S | 22.10 | 5,000 | 110,497 | 126,349 | 131.3 K to 126.3 K (-3.81 %) |
Mar 03 2004 | NOVN | NOVEN PHARMACEUTIC ... | STRAUSS ROBERT C | President, CEO & Ch ... | Sell | S | 22.23 | 10,000 | 222,300 | 131,349 | 141.3 K to 131.3 K (-7.07 %) |